Controlled trial of hydroxocobalamin and riboflavine in Nigerian ataxic neuropathy.
The results are presented of a double-blind therapeutic trial of hydroxocobalamin and riboflavine in Nigerian patients suffering from a degenerative neuropathy. Although no benefit from either vitamin was demonstrated, this may reflect the inadequacy of the dosages used. The results are discussed in relation to the hypothesis that dietary cyanide and cyanogens are responsible, at least in part, for the occurrence of this disease in a malnourished population.
D001259:Ataxia / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D006879:Hydroxocobalamin / Q000008:administration & dosage*; D008297:Male; D002365:Manihot; D009422:Nervous System Diseases / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology; D009549:Nigeria; D010919:Placebos; D012256:Riboflavin / Q000008:administration & dosage*; D013861:Thiocyanates / Q000097:blood; D014805:Vitamin B 12 / Q000097:blood
D010919:Placebos; D013861:Thiocyanates; D014805:Vitamin B 12; D006879:Hydroxocobalamin; D012256:Riboflavin